Free tool
Cell therapy stocks
We cover 6 companies grouped under the Cell therapy theme. The median market value in the group is $32.56M. Across the group, the median move over the past trading day is −4.57%. Price change over the past year runs from −57.1% to −4.7% across the middle 80 percent of the group, with a median of −42.4%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
6 of 86 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| V3V.DE | FamiCord AG | $58.07M | Micro cap | −60.95% |
| HEMO.L | Hemogenyx Pharmaceuticals Plc | $54.52M | Micro cap | +11.32% |
| PTG.WA | Poltreg S.A. | $34.29M | Micro cap | −20.69% |
| PSH0.DE | Sernova Biotherapeutics Inc | $30.82M | Micro cap | −37.50% |
| F98.F | CytoMed Therapeutics Limited | $10.68M | Micro cap | −53.29% |
| BSFA.L | BSF Enterprise Plc | $2.93M | Micro cap | −47.38% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.